The abstract is read at the publisher; the summary is JClub's.
Resistance-guided treatment for uncomplicated gonorrhea in the United States is cost-neutral up to $48 per test at 15% ceftriaxone resistance prevalence, with higher value in MSM.
- Why it matters: Rising antimicrobial resistance in Neisseria gonorrhoeae threatens ceftriaxone’s effectiveness, and the economic case for investing in resistance testing is unclear across near-term savings and longer-term resistance and development costs.
- What they did: An individual-level stochastic simulation modeled diagnosis and treatment pathways in the United States using 2025 USD costs, comparing ciprofloxacin-only, ciprofloxacin + ceftriaxone, and triple-target testing (including a novel drug A) across resistance scenarios.
- The result: Per-episode cost-neutral thresholds ranged from near $0 to $48 per test, and at 50% ciprofloxacin resistance with 5% ceftriaxone resistance the population-weighted thresholds were $7 (95% UI $3–$11) and $13 (95% UI $8–$19); in MSM, including system-level emergence and avoided development costs raised per-test value to $31–$114 for single-target and $73–$106 for triple-target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.